The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 20, 2021

Filed:

Aug. 28, 2017
Applicant:

Hackensack University Medical Center, Hackensack, NJ (US);

Inventor:

Yong Zhao, River Edge, NJ (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/071 (2010.01); A61K 35/39 (2015.01); A61K 35/19 (2015.01); C12N 15/87 (2006.01); A61K 38/17 (2006.01); C12N 5/0786 (2010.01); A61K 35/15 (2015.01); A61K 38/00 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0678 (2013.01); A61K 35/19 (2013.01); A61K 35/39 (2013.01); A61K 38/17 (2013.01); C12N 5/0645 (2013.01); C12N 5/0676 (2013.01); C12N 15/87 (2013.01); A61K 35/15 (2013.01); A61K 38/00 (2013.01); C07K 16/2896 (2013.01); C12N 2502/115 (2013.01);
Abstract

The described invention provides a method of functionally reprogramming adult cells to an immature cell type that expresses one or more embryonic biomarkers with a platelet rich fraction comprising platelet-like cells from umbilical cord blood or peripheral blood, and expanding the immature cell type in vitro under culture conditions to generate an insulin-producing cell population that expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells. It further provides a pharmaceutical composition comprising a cell product containing a therapeutic amount of an insulin-producing cell population, wherein the insulin-producing cell population expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells, and a method for treating a recipient subject suffering from a disease characterized by hyperglycemia with the pharmaceutical composition.


Find Patent Forward Citations

Loading…